- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04876859
Comparative Study Between Steroid Plus Anesthetic Block and CRF in Participants With Hip Osteoarthritis
May 23, 2023 updated by: João Luiz Q. Durigan, University of Brasilia
Conventional Radiofrequency of Anterior Sensory Branches in Chronic Hip Pain Due to Hip Osteoarthritis: A Randomized Clinical Trial
This will be a prospective, multi-center, double-blinded, randomized study designed to compare the efficacy of Conventional Radiofrequency (CRF) and the anesthetic block of the anterior sensory branches to the hip to control pain and improve function related to hip osteoarthritis.
Study Overview
Status
Suspended
Conditions
Detailed Description
This prospective, double-blinded (participant and outcome assessor) clinical trial was designed to investigate the results of the intervention Continuous Radiofrequency (CRF) in the treatment of participants with chronic hip pain secondary to hip osteoarthritis.
Participants will be randomized in a 2-arm, parallel groups.
The intervention group will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (Betamethasone Dipropionate 5 mg/ml + Betamethasone Sodium Phosphate 2 mg/ml) for each branch, followed by denervation with CRF (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° C in a single cycle of 90 min.
The sham group will be submitted to the same anesthetic block, followed by a simulation of CRF use.
The surgeon performing the procedures will only be informed of the randomization after completing the anesthetic block on the participants to avoid bias at its accuracy.
Participants will be evaluated at four follow-up: before intervention and after 1, 12, and 24 weeks, to access the Western Ontario and McMaster Universities score (WOMAC) as the primary outcome.
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gilvan F. Vaz, MD
- Phone Number: + 55 61 991527220
- Email: gilvanvaz@gmail.com
Study Locations
-
-
Distrito Federal
-
Brasília, Distrito Federal, Brazil, 70673-900
- Hospital das Forças Armadas
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants 18 years or older
- Symptomatic unilateral hip osteoarthritis (OA)
- Pain for more than 6 months in the groin, anterior, anterolateral ou lateral region
- OA radiologically classified as Kellgren and Lawrence Tipo II-IV,
- VAS ≥ 4
- Considered non-responder to conservative treatment for the participant for 6 months.
- In case of difficulty in selecting participants with symptomatic unilateral OA, symptomatic bilateral hip OA will be admitted and submitted to the same treatment on both sides, after notification and approval from the Ethic Board of each institution involved.
Exclusion Criteria:
- Participants with radiculopathy ipsolateral
- Knee OA ipsolateral,
- Previous hip arthroplasty
- Pain exclusively in the posterior region of the hip
- Infiltration of the hip for less than 3 months
- Neurological disease compromising gait
- Peripheral neuropathy
- Psychiatric disease that compromise collaboration with the protocol
- Implanted pacemaker
- Prothrombin Activity Time (PT/INR) > 3 and
- Litigation process related to the disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Conventional Radiofrequency Group
Will be submitted to an anesthetic block of the sensory branches of femoral and obturator nerves to the hip, with 1 ml of 1% lidocaine with 1ml of steroid (Betamethasone Dipropionate 5 mg/ml + Betamethasone Sodium Phosphate 2 mg/ml) for each branch, followed by denervation with CRF (22¬gauge 5¬mm active tip cannula, 10cm in length) with the tip temperature set at 90° C in a single cycle of 90 min.
|
Steroid and anesthetic extra articular injection followed by denervation using CRF at 90 celsius degree during a period 90 minutes at the sensitive branches of obturator and femoral nerve, separately.
|
Sham Comparator: Anesthetic plus steroid group
The sham group will be submitted to the same anesthetic block as described in the intervention group, followed by a simulation of CRF use.
|
Corticosteroid and anesthetic extra articular injection at the sensitive branches of obturator and femoral nerve, only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of Life (WOMAC)
Time Frame: Baseline to 24 weeks ± 1 week.
|
The Western Ontario and McMaster Universities (WOMAC) is a self-administered health status measure and consists of 24 items divided into three domains, which are pain (5 questions), stiffness (2 questions), and physical function (17 questions), validated to patients with hip or knee osteoarthritis, available in a 5-point Likert scale, ranging from 0 to 96 points.This questionnaire is translated and validated in portuguese.
|
Baseline to 24 weeks ± 1 week.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Pain Visual Analogue Scale
Time Frame: Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
The pain visual analogue scale (VAS) is a unidimensional measure of pain intensity, in a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme, "no pain" (score 0) and " worst pain ever" (score 100).
|
Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Change in Harris Hip Score (HHS)
Time Frame: Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
The Harris Hip Score (HHS) is a joint-specific measure, and it consists of two sections: questions and a physical examination, including a range of motion and deformity items.
The score has a maximum of 100 points with a maximum of 44 points for pain, 47 for function, 4 points for absence of deformity, and 5 points for a range of motion.
The highest score of 100 points indicates the best function and no pain.
|
Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Pain Medication Intake
Time Frame: Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
To evaluate pain medication we will use a scale ranging from 0 to 4 (0= no medication; 0 = no medication; 1= use of dipyrone or paracetamol; 2= use of NSAIDs; 3= use of opiate derivatives; 4= routinely scheduled opiate derivatives), considering the last 48 hours.
|
Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Change in Hip muscles Isometric Peak Force
Time Frame: Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
To examine isometric muscle force, a Lafayette Manual Muscle Testing System Model-01165 (Lafayette Instrument Company, Lafayette IN, USA) will be used to access Peak Force of hip flexors, abductors, adductors and extensors.
|
Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Change in Hip muscles Time to Reach Peak Force
Time Frame: Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
To examine isometric muscle force, a Lafayette Manual Muscle Testing System Model-01165 (Lafayette Instrument Company, Lafayette IN, USA) will be used to access Time to Reach Peak Force of hip flexors, abductors, adductors and extensors.
|
Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Change in Hip muscles Average Force
Time Frame: Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
To examine isometric muscle force, a Lafayette Manual Muscle Testing System Model-01165 (Lafayette Instrument Company, Lafayette IN, USA) will be used to access Average Force of hip flexors, abductors, adductors and extensors.
We will also determine intra and inter-rater reliability for isometric force of hip flexors, abductors, adductors and extensors.
|
Baseline, 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Evaluation of intra and inter-rater reliability of Lafayette Manual Muscle Testing System Model-01165 in subjects with hip Osteoarthritis.
Time Frame: Baseline
|
To determine intra and inter-rater reliability of the Hand lend dynamometer Lafayette Manual Muscle Testing System Model-01165 (Lafayette Instrument Company, Lafayette IN, USA) in accessing peak force, time to reach peak force and average force of hip flexors, abductors, adductors and extensors, the first 20 participants included in this study will be evaluated by the principal investigator and outcome assessor at the baseline.
|
Baseline
|
Change in Global Satisfaction
Time Frame: 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
To evaluate participant satisfaction, we will use 5 points Likert Scale, ranging from 0 to 4 (0= none _ no good at all, ineffective intervention; 1= poor _ some effect but unsatisfactory; 2= fair _ reasonable effect but could be better; 3= good _ satisfactory effect with occasional episodes of pain or stiffness; 4= excellent _ ideal response, virtually pain-free).
|
1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Effects
Time Frame: 1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
To examine the incidence of adverse effects, a questionnaire will be apply to investigate the occurrence of: Hematoma, paresthesia, weakness, worsening of pain, worsening of function or any other adverse effect that participants attribute to the procedure performed.
|
1 week, 12 weeks ± 1 week and 24 weeks ± 1 week.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: João Durigan, PhD, Universidade de Brasília
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 8, 2021
Primary Completion (Anticipated)
October 31, 2024
Study Completion (Anticipated)
November 30, 2024
Study Registration Dates
First Submitted
April 26, 2021
First Submitted That Met QC Criteria
May 4, 2021
First Posted (Actual)
May 7, 2021
Study Record Updates
Last Update Posted (Actual)
May 24, 2023
Last Update Submitted That Met QC Criteria
May 23, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAE: 40347320.1.1001.0025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
-
Apurano Pharmaceuticals GmbHRecruitingPain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain ChronicGermany
Clinical Trials on CRF of anterior sensitive branches to the hip
-
Mount Carmel Health SystemActive, not recruitingHip Fractures
-
Aydin Adnan Menderes UniversityRecruiting
-
Ataturk UniversityCompletedAnesthesia, Local | Cesarean Section Complications | HypotensionTurkey
-
University Health Network, TorontoUnknownBreast Pain
-
University of IoanninaCompleted
-
Ain Shams UniversityCompletedRespiratory Distress Syndrome, NewbornEgypt
-
Eskisehir Osmangazi UniversityCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Metabolic Therapy Inc.UnknownAlzheimer Disease
-
University of FloridaALS AssociationRecruiting